How to cite item

KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment

   
@article{TLCR31206,
	author = {Amy Lauren Cummings and Kate M. Santoso and Jonathan W. Goldman},
	title = {KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment},
	journal = {Translational Lung Cancer Research},
	volume = {8},
	number = {5},
	year = {2019},
	keywords = {},
	abstract = {With 15 new non-small cell lung cancer (NSCLC) United States Food & Drug Association (FDA) approvals in the past 5 years, the alignment of academia, pharmaceutical companies, and government regulatory agencies to develop better cancer therapies and quickly make them available to patients has led to a rapidly evolving standard-of-care (1).  While undoubtedly beneficial to NSCLC patients, one ramification is that the environment in which a clinical trial is designed may not be same one in which its results are reported. Such is the case with KEYNOTE-021 Cohorts D and H (KN-021 D/H) (2).},
	issn = {2226-4477},	url = {https://tlcr.amegroups.org/article/view/31206}
}